.GAMMA.-AMINO-.BETA.-HYDROXYBUTYRIC ACID

Details

Stereochemistry	RACEMIC
Molecular Formula	C4H9NO3
Molecular Weight	119.1192
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of .GAMMA.-AMINO-.BETA.-HYDROXYBUTYRIC ACID

Structure Search

SMILES

NCC(O)CC(O)=O

InChI

InChIKey=YQGDEPYYFWUPGO-UHFFFAOYSA-N

InChI=1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)

HIDE SMILES / InChI

Description
Sources: http://www.fda.gov/ohrms/dockets/dockets/98n0182/nom005a.pdf
Curator's Comment: description was created based on several sources, including: https://www.antiaging-systems.com/38-aminohydroxybutyric-acid-gabob-buxamin https://www.ncbi.nlm.nih.gov/pubmed/2854014 https://en.wikipedia.org/wiki/Gamma-Amino-beta-hydroxybutyric_acid

4-Amino-3-hydroxybutanoic acid (GABOB) is an endogenous ligand found in the central nervous system in mammals. γ-Amino-β-hydroxybutyric acid is a derivative of the neurotransmitter GABA. It has been claimed to be of value in neurological disorders and to have an antihypertensive effect. γ-Amino-β-hydroxybutyric acid can help overcome stress and anxiety, improve learning and boost memory function. It is also known to increase growth hormone levels, which help the body heal and rejuvenate itself. There are no reported side effects of γ-Amino-β-hydroxybutyric acid when taken at therapeutic dosages. At high dosages, some slight drowsiness may occur. Adverse effects have included dizziness and anorexia also.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA receptor rho-1 subunit 3 Target ID: CHEMBL3561 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23019493	Agonist 2678		19.1 µM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Primary and secondary convulsive syndromes 1 Sources: http://app7.infarmed.pt/infomed/download_ficheiro.php?med_id=3748&tipo_doc=fi	Primary	Approved 8429	GABOMADE Approved Use Adjuvant therapy of primary and secondary syndromes comitial and convulsive states the most varied etiology, especially in children. Launch Date 2005
Mental retardation 1 Sources: http://app7.infarmed.pt/infomed/download_ficheiro.php?med_id=3748&tipo_doc=fi	Primary	Approved 8429	GABOMADE Approved Use Indicated for the mental retardation treatment Launch Date 2005
Headache 47 Sources: http://app7.infarmed.pt/infomed/download_ficheiro.php?med_id=3748&tipo_doc=fi	Primary	Approved 8429	GABOMADE Approved Use Indicated for the headache treatment Launch Date 2005

PubMed

Title	Date	PubMed
The inhibitory action of beta-hydroxy-gamma-aminobutyric acid upon the seizure following stimulation of the motor cortex of the dog.	1959 Mar 12	13642322
[Gamibetal (gamma-amino-beta-hydroxybutyric acid--GABOB) in the treatment of epilepsy].	1967 Mar-Apr	6082678

Patents

Sample Use Guides

In Vivo Use Guide

Anxiety or stress: take 1 × 500mg tablet, or 2 × 250mg daily. For epilepsy take 2 × 500mg tablets twice daily.

Route of Administration: Oral

In Vitro Use Guide

Upon spinal ganglion cells, to which the GABOB is added in 0.5 mg/cc, is effective for maintenance and differentiation of nerve cells.

Name

Type

Language

.GAMMA.-AMINO-.BETA.-HYDROXYBUTYRIC ACID

Systematic Name

English

GAMIBETAL

Brand Name

English

4-AMINO-3-HYDROXYBUTYRIC ACID [INCI]

Common Name

English

BUTANOIC ACID, 4-AMINO-3-HYDROXY-, (±)-

Common Name

English

GAMMA-AMINO-BETA-HYDROXYBUTYRIC ACID

Systematic Name

English

GABOB

Common Name

English

4-AMINO-3-HYDROXYBUTYRIC ACID

Official Name

English

GAMMA-AMINO-BETA-HYDROXYBUTYRIC ACID [JAN]

Common Name

English

NSC-40244

Code

English

BUKSAMIN

Common Name

English

(±)-4-AMINO-3-HYDROXYBUTYRIC ACID

Systematic Name

English

4-AMINO-3-HYDROXYBUTYRIC ACID [MI]

Common Name

English

GABOMADE

Brand Name

English

4-amino-3-hydroxybutyric acid [WHO-DD]

Common Name

English

BUTYRIC ACID, 4-AMINO-3-HYDROXY-, DL-

Common Name

English

4-AMINO-3-HYDROXYBUTYRIC ACID [MART.]

Common Name

English

Code System Code Type Description

CAS

352-21-6